(firstQuint)Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer.

 Participants with stage IA-IIIA, surgically resectable lung adenocarcinoma with an activating alteration in ALK, ROS1 or MET will receive neoadjuvant treatment with crizotinib.

 This neoadjuvant treatment will last 6 weeks and on the last day of dosing of crizotinib, participants will undergo surgical resection, followed by 5 years of follow-up via chart review.

.

 Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer@highlight

This study will evaluate the efficacy of crizotinib as induction therapy in participants with surgically resectable ALK rearrangement, ROS1 rearrangement, or MET exon 14 mutation positive NSCLC.

